secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2026-08-05T21:17:20+00:00
Accession:  0001104659-26-091269
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie prices $10B multi-tranche senior notes offering to fund Apogee acquisition
--------------------------------------------------------------------------------

- Issued $10B aggregate principal across 9 tranches: floating rate notes due 2028, fixed-rate notes from 2028 to 2066 with coupons 4.500% to 6.100%.
- Net proceeds ~$9.93B; closing expected August 18, 2026.
- Proceeds to partially fund AbbVie's cash payment obligations for Apogee acquisition and for general corporate purposes, including debt repayment.
- The offering reduces commitments under AbbVie's $10B 364-day delayed draw term loan facility related to the Apogee acquisition.
- Underwriters include Morgan Stanley, BofA Securities, J.P. Morgan, SG Americas Securities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000110465926091269/0001104659-26-091269-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000110465926091269/tm2621452d4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-091269

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer